drugset / Trial / NCT04276636

Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency

NCT04276636 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Aims:Prospectively observe the effects of Caltrate supplementation on the chronic course of Crohn's disease patients, analyze whether the effect of Caltrate on CD patients is affected by factors such as disease site, disease activity, treatment, etc.Provide a certain theoretical basis for "precision treatment" for CD patients in the future. Design:It is a prospective cohort study. Investigators include a total of 60 participants with CD according to the inclusion and exclusion criteria, and divide them into two groups to assess their initial disease activity and detect related indicators. At the same time,Investigators detect the Vitamin D Gene gene polymorphisms in all participants.One group is given Caltrate 0.6g per day orally, and the control group do not intervene. After 12 months, re-evaluate the disease activity and retest the relevant indicators, and use statistical methods to analyze whether Caltrate supplementation treatment can increase the serum 25 (OH) D level of CD participants, improve the condition of CD participants,relationship with Vitamin D Gene Polymorphism,and analyze the effect of Caltrate on participants with CD is affected by factors such as disease site, disease activity, and treatment.

Timeline

Start
2020-10
Primary completion
2021-03
Completion
2021-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Caltrate Pill Unknown 0.6 g Oral